These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 23225540)

  • 1. Use of regadenoson in end-stage renal disease.
    Iskandrian AE; Hage FG; Heo J
    J Nucl Cardiol; 2013 Apr; 20(2):182-4. PubMed ID: 23225540
    [No Abstract]   [Full Text] [Related]  

  • 2. The safety and tolerability of regadenoson in patients with end-stage renal disease: the first prospective evaluation.
    Doukky R; Rangel MO; Wassouf M; Dick R; Alqaid A; Morales Demori R
    J Nucl Cardiol; 2013 Apr; 20(2):205-13. PubMed ID: 23239416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prognostic value of regadenoson SPECT myocardial perfusion imaging in patients with end-stage renal disease.
    Doukky R; Fughhi I; Campagnoli T; Wassouf M; Ali A
    J Nucl Cardiol; 2017 Feb; 24(1):112-118. PubMed ID: 26582040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The EXERRT trial: "EXErcise to Regadenoson in Recovery Trial": A phase 3b, open-label, parallel group, randomized, multicenter study to assess regadenoson administration following an inadequate exercise stress test as compared to regadenoson without exercise for myocardial perfusion imaging using a SPECT protocol.
    Thomas GS; Cullom SJ; Kitt TM; Feaheny KM; Ananthasubramaniam K; Gropler RJ; Jain D; Thompson RC
    J Nucl Cardiol; 2017 Jun; 24(3):788-802. PubMed ID: 28224449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prognostic value of regadenoson myocardial perfusion imaging.
    Hage FG; Ghimire G; Lester D; Mckay J; Bleich S; El-Hajj S; Iskandrian AE
    J Nucl Cardiol; 2015 Dec; 22(6):1214-21. PubMed ID: 25677160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic and prognostic significance of ischemic electrocardiographic changes with regadenoson-stress myocardial perfusion imaging.
    Doukky R; Olusanya A; Vashistha R; Saini A; Fughhi I; Mansour K; Nigatu A; Confer K; Sims SA
    J Nucl Cardiol; 2015 Aug; 22(4):700-13. PubMed ID: 25907352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of heart rate response during regadenoson stress myocardial perfusion imaging in patients with end stage renal disease.
    AlJaroudi W; Campagnoli T; Fughhi I; Wassouf M; Ali A; Doukky R
    J Nucl Cardiol; 2016 Jun; 23(3):560-9. PubMed ID: 26293358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regadenoson use in chronic kidney disease and end-stage renal disease: A focused review.
    Vij A; Golzar Y; Doukky R
    J Nucl Cardiol; 2018 Feb; 25(1):137-149. PubMed ID: 28653271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Performance and safety profile of regadenoson myocardial perfusion imaging: first experience in Greece.
    Koutsikos J; Angelidis G; Zafeirakis A; Mamarelis I; Vogiatzis M; Ilia E; Lazaridis K; Demakopoulos N
    Hell J Nucl Med; 2017; 20(3):232-236. PubMed ID: 29177261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regadenoson pharmacologic stress for myocardial perfusion imaging: a three-way comparison between regadenoson administered at peak exercise, during walk recovery, or no-exercise.
    Thompson RC; Patil H; Thompson EC; Thomas GS; Al-Amoodi M; Kennedy KF; Bybee KA; Iain McGhie A; O'Keefe JH; Oakes L; Bateman TM
    J Nucl Cardiol; 2013 Apr; 20(2):214-21; quiz 222-6. PubMed ID: 23233371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Off-label, but on-target: use of regadenoson with exercise.
    Hendel RC; Frost L
    J Nucl Cardiol; 2013 Apr; 20(2):179-81. PubMed ID: 23143811
    [No Abstract]   [Full Text] [Related]  

  • 12. Cardiovascular risk assessment with regadenoson SPECT MPI in patients with end-stage renal disease is safe, effective, and well tolerated: Does it matter?
    Miller EO; Schwartz RG
    J Nucl Cardiol; 2017 Feb; 24(1):119-121. PubMed ID: 26626782
    [No Abstract]   [Full Text] [Related]  

  • 13. Aminophylline and caffeine for reversal of adverse symptoms associated with regadenoson SPECT MPI.
    Doran JA; Sajjad W; Schneider MD; Gupta R; Mackin ML; Schwartz RG
    J Nucl Cardiol; 2017 Jun; 24(3):1062-1070. PubMed ID: 27025843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lessons from regadenoson and low-level treadmill/regadenoson myocardial perfusion imaging: initial clinical experience in 1263 patients.
    Kwon DH; Cerqueira MD; Young R; Houghtaling P; Lieber E; Menon V; Brunken RC; Jaber WA
    J Nucl Cardiol; 2010 Oct; 17(5):853-7. PubMed ID: 20414756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of integrating heart rate response with perfusion imaging on the prognostic value of regadenoson SPECT myocardial perfusion imaging in patients with end-stage renal disease.
    Gomez J; Fughhi I; Campagnoli T; Ali A; Doukky R
    J Nucl Cardiol; 2017 Oct; 24(5):1666-1671. PubMed ID: 27251142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of changes in perfusion defect size during serial regadenoson myocardial perfusion imaging on cardiovascular outcomes in high-risk patients.
    El-Hajj S; AlJaroudi WA; Farag A; Bleich S; Manaoragada P; Iskandrian AE; Hage FG
    J Nucl Cardiol; 2016 Feb; 23(1):101-12. PubMed ID: 26017713
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prognostic utility of regadenoson SPECT myocardial perfusion imaging in patients with end-stage renal disease: The largest cohort to date.
    Kolkailah AA; Iskander M; Iskander F; Patel PP; Khan R; Doukky R
    J Nucl Cardiol; 2022 Feb; 29(1):101-110. PubMed ID: 32632913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regadenoson: a focused update.
    Ghimire G; Hage FG; Heo J; Iskandrian AE
    J Nucl Cardiol; 2013 Apr; 20(2):284-8. PubMed ID: 23229649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Marked ST-segment elevations during regadenoson pharmacologic nuclear stress testing.
    Chan N; Kataria V; Kim BS; Raimondi P; Makaryus JN
    J Nucl Cardiol; 2020 Jun; 27(3):1071-1075. PubMed ID: 30887384
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparison of the prognostic value of regadenoson and adenosine myocardial perfusion imaging.
    Farzaneh-Far A; Shaw LK; Dunning A; Oldan JD; O'Connor CM; Borges-Neto S
    J Nucl Cardiol; 2015 Aug; 22(4):600-7. PubMed ID: 25987234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.